Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day

01 Feb, 2016, 16:30 ET from Vanda Pharmaceuticals Inc.

WASHINGTON, Feb. 1, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel therapies addressing high unmet medical needs, today announced that members of its management team will participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day on Tuesday, February 2, 2016 in New York City.

For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Investor Contact: Jim Kelly Senior Vice President and Chief Financial Officer Vanda Pharmaceuticals Inc. (202) 734-3428 jim.kelly@vandapharma.com

 

SOURCE Vanda Pharmaceuticals Inc.



RELATED LINKS

http://www.vandapharma.com